ArticleBMC research notes2026
Incompatibility of resazurin to detect viable cells in lignin biomaterials: a cautionary study.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe nanoparticles prepared from lignin polymer and its methacrylated derivative have gained significant attention in the biomedical field owing to their superior biosafety profile. Here, this study aims towards the synthesis of the methacrylated lignin nanoparticles (MLNPs) using the nanoprecipitation method and understanding their biocompatibility in A549 cells using the resazurin assay.
resultsIn our study, the nanoprecipitation method yielded a stable suspension of MLNPs having sub-200 nm size. When incubated with A549 cells, initially, these nanoparticles showed cytotoxicity and reduced biocompatibility from the well-known resazurin assay. However, careful microscopic examination of the cells showed healthy and well-adhered A549 cells with normal cobblestone-like epithelial morphology. Hence, we performed a detailed analysis of MLNPs to understand their interaction with resazurin with respect to concentration and time while keeping pristine lignin nanoparticles (LNPs) as a control. We found that LNPs and MLNPs interfered with resazurin assay, leading to false-positive results. Our study highlights a significant drawback in the use of resazurin assay for these nanoparticles and emphasizes the critical need for alternative approaches to evaluate their biocompatibility. In an attempt to find alternative, conventional MTT assay offered highly reproducible biocompatibility results without any interference during evaluating the cytotoxicity of these nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.